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Abstract While overall survival (OS) has historically been
the primary endpoint for clinical trials in oncology, progres-
sion-free survival (PFS) has gained acceptance as a valuable
surrogate endpoint. However, there are no known published
reports about the value of PFS from the patient’s perspective.
We developed a questionnaire that included items regarding
quality of life (QoL) and the importance of different treatment
outcomes and presented hypothetical scenarios for which
respondents were asked to indicate their preferences con-
cerning treatments as they relate to PFS. 282 women with
metastatic breast cancer (MBC), ranging in age from 21 to
80 years completed an online version of this questionnaire.
The majority of women (66 %) had been diagnosed with
MBC within the previous 3 years and 56 % had been told their
MBC had progressed. When asked to rank five treatment
characteristics from most important to least important,
respondents ranked ‘‘extending PFS’’ as the second most
important treatment outcome after OS. When presented with a
hypothetical scenario of two women receiving different
treatments, respondents preferred the treatment that resulted
in longer PFS (16 vs. 12 months), even when OS and side
effects were assumed to be equal. Specifically, when asked to
consider which woman within the hypothetical scenario had
better QoL, physical functioning, and emotional well-being,
respondents more often chose the woman who experienced
longer PFS (QoL: 40 vs. 6 %; physical functioning: 32 vs.
8 %; emotional well-being: 58 vs. 6 %) compared to the
woman within the hypothetical scenario who had a shorter
time of progression. Respondents rated their own QoL highest
after being told their MBC was responding to treatment (mean
score 76.6) versus after the initial diagnosis of breast cancer
and MBC (68.5 and 60.3). These findings suggest that
extending PFS is an important treatment outcome and, from a
patient perspective, improves overall QoL, physical func-
tioning, and emotional well-being.
Keywords Metastatic breast cancer  Progression-
free survival  Quality of life  Questionnaire
Introduction
While overall survival (OS) is often the preferred endpoint
measured in oncology trials, progression-free survival
(PFS) has become more common as an endpoint of primary
or secondary interest, in part because of the additional time
needed to assess OS [1–6]. While OS estimates can be
impacted by post-progression treatment heterogeneity and
crossover [7], PFS provides a direct measure of treatment
effect on the course of disease that is not susceptible to
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such bias. While PFS, from a clinician’s perspective,
measures the amount of time before the disease progresses,
research regarding its value from a patient’s perspective is
limited. One recently published study reported that patients
with renal cell carcinoma consider PFS to be an important
outcome, and that they are willing to accept higher treat-
ment-related risks to increase their PFS [8]. However, no
published literature on the value of PFS from the per-
spective of patients with metastatic breast cancer (MBC)
has been found.
The value of PFS can be difficult to quantify since many
variables play a role in determining both OS and the quality
of a patient’s life during this period of time. However,
measures of emotional well-being and quality of life (QoL)
can help describe the value of PFS, and are common
metrics in oncology studies [9–13]. While better QoL has
been shown to be associated with longer OS for cancer
patients [14, 15], there are no published data describing the
association of QoL or emotional well-being with PFS.
The goal was to conduct a multi-stage study in which we
would first conduct concept elicitation interviews of
patients with MBC, use the findings from this qualitative
research to draft a questionnaire, pilot test the question-
naire to finalize it, and then implement the final question-
naire in a study. We sought to obtain data regarding the
value of PFS in patients with MBC, to describe the gain in
value from PFS, and to investigate how that value differed
across relevant patient and clinical characteristics.
Methods
Study protocol and selection of participants
The study was conducted in three consecutive parts. Parts I
and II involved the creation and pilot testing of a newly
developed self-administered questionnaire, and then data
were collected online from respondents with MBC during
Part III. For all parts of the study, eligible patients were
female, at least 18 years of age, with a clinical diagnosis of
MBC, able to speak and read English and willing to sign an
informed consent form. Patients eligible for Part III also
had to be willing to self-administer the online question-
naire. The study was approved by a central institutional
review board. Patients from the United States were
recruited using internet advertisements for the study posted
on websites devoted to breast cancer.
One-on-one in-depth interviews with women with MBC
During Part I, one-on-one in-depth telephone interviews
were conducted with 19 women with MBC to determine
important issue areas related to PFS from a patient’s
perspective. While the diagnosis of MBC had significantly
impacted all areas of QoL for those interviewed, the
emotional impact (anxiety, depression, isolation, fear,
feeling down, and uncertainty) was noted by all, but one,
of the 19 women interviewed. Additionally, of the 8
whose disease had not progressed, 5 indicated that they
would likely be more aggressive with their treatment if
they were to learn their cancer had progressed. The vast
majority of the 11 whose disease had progressed were
more willing to accept side effects of more aggressive
treatments (specific number not available). When asked
about the most important ways metastatic cancer currently
affects their lives, aspects such as being consumed with
doctor appointments, managing side effects of treatment,
limitations in ability to work or get around, and impact on
family members as well as emotional aspects were often
mentioned. Finally, the value placed on PFS varied and
was clearly affected by many factors, including age and
progression status. Nearly all of the progressed women
felt they would be willing to explore a treatment option
that would give them 4 months of PFS, whereas those in
the non-progressed group provided mixed responses.
Based on this information, a self-administered question-
naire was developed. The questionnaire was pre-tested in
Part II with a subset of the women (8 of the 19) who took
part in the Part I interviews. Minor modifications were
made to the questionnaire, and a final version of the
MBC-Progression (MBC-P) questionnaire was developed
for use in Part III.
Overview of the MBC-P questionnaire
The final version of the MBC-P included items assessing
overall health and well-being, cancer worry, and impact on
patients’ physical and emotional status (energy levels,
social isolation, activity restrictions, limitations, etc.) as
well as the hypothetical scenario regarding PFS. Many of
the impact questions were presented in the form of agree-
ment statements, and participants were asked to respond to
each statement using a scale ranging from 1 (strongly
agree) to 5 (strongly disagree). Examples of these state-
ments include, ‘‘I can live with side effects as long as
treatment is working,’’ and ‘‘The length of time I have
before my disease progresses is more important to me than
the quality of my days.’’ Several types of data were col-
lected: respondents provided information on their own
health and well-being; they reflected on QoL and well-
being associated with their own treatment; and they offered
their opinion regarding the experience of two women in a
unique hypothetical scenario. Specifically, respondents
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were presented with a hypothetical scenario in which one
woman (Woman A) receives treatment X for 1 year
(12 months) before her cancer progresses, while another
woman (Woman B) receives treatment Y for 1 year and
4 months (16 months) before her cancer progresses.
Respondents were further told that OS and side effects
were equivalent for the two women, and were then asked to
consider which woman had higher overall QoL, physical
functioning, and emotional well-being. The precise word-
ing of the hypothetical scenario posed, as well as additional
examples of items from the MBC-P, appear in Appendix.
The MBC-P contained a total of 41 items and took
approximately 15 min to complete. It was administered
online between January and May of 2011. Completed
online entries were thoroughly screened to ensure that
multiple surveys from the same computer (IP address) were
not included.
Statistical analysis
Statistical analysis was performed on data collected in Part
III. Means, standard deviations, and ranges were calculated
for continuous variables such as age and length of time
since MBC diagnosis, as well as for survey items where
patients provided ranked or rated responses. Frequencies
and percentages were calculated for categorical data, and
some measures were stratified by disease progression, age,
or time since MBC diagnosis. Since these outcomes were
exploratory in nature and intended to drive future hypoth-
eses, only a few statistical comparisons were made using
independent sample t tests, analysis of variance or v2 tests.
Differences were considered statistically significant at the
0.05 level. Otherwise, descriptive results, without testing
for statistical differences, are presented. All analyses were
performed using SPSS, version 19.0.
Results
Study population
A total of 547 people initiated the online survey for Part III.
From this initial set of respondents, 265 were deemed inel-
igible for the following reasons: incomplete entries
(n = 144), duplicate entry (n = 101), male (n = 7), did not
provide consent (n = 5), or for other eligibility issues
(n = 8). The remaining 282 women with MBC were deemed
eligible and completed the online survey. Demographic and
clinical information on these 282 patients is provided in
Table 1. The mean age of respondents was 50 years and
ranged from 21 to 80 years of age. Respondents were pri-
marily white (88 %), and the majority (90 %) had at least
some college education. Nearly half of the participants
(45 %) were first diagnosed with breast cancer more than
5 years ago, and roughly two-thirds (68 %) were first
Table 1 Demographic and clinical information of Part III respon-
dents (n = 282)
n %
Age
Mean, SD 50.2 (10.8)
Range 21–80
Age \50 (n, %) 128 45.4
Age C50 (n, %) 154 54.6
Race/ethnicity (n, %)
Caucasian/White 249 88.3
Latino or Hispanic 6 2.1
African American/Black 16 5.7
Asian or Pacific Islander 7 2.5
Native American or Alaskan native 1 \1
Other 3 1.1
Highest education (n, %)
High school degree or GED or less 25 8.9
Some college 61 21.6
College degree 107 37.9
Graduate or professional degree 86 30.5
Other 3 1.1
Breast cancer first diagnosed (n, %)
\1 year ago 48 17.0
1–5 years ago 108 38.3
[5 years ago 128 45.4
Time since MBC first diagnosed (n, %)
\1 year ago 89 31.6
1–3 years ago 96 34.0
[3 years ago 97 34.4
Ever told MBC progressed? (n, %)
Yes 159 56.4
No 123 43.6
Table 2 Statements most strongly agreed with by respondents
Statement Mean (SD)
scorea
95 % CI
I can complete tasks in a timely manner 2.73 (1.23) [2.59, 2.88]
I can accomplish what I like to get done 2.70 (1.19) [2.56, 2.84]
I have had enough energy 2.65 (1.07) [2.52, 2.77]
I have felt hopeful about the future 2.59 (1.11) [2.46, 2.72]
I can take care of myself 2.28 (1.15) [2.14, 2.42]
I can put some aspects of my life on hold 2.09 (1.12) [1.96, 2.22]
I enjoy every day to the fullest 2.01 (1.01) [1.89, 2.13]
I can live with side effects as long as the
treatment is working
1.74 (1.00) [1.63, 1.86]
a Responses range from 1 (strongly agree) to 5 (strongly disagree)
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diagnosed with MBC more than a year ago. Over half (56 %)
had been told that their MBC had progressed.
Agreement statements
Table 2 displays the mean scores of the most strongly agreed
with statements (lower scores indicate stronger agreement on
average). Statements respondents agreed most strongly with
included, ‘‘I can live with side effects as long as the treatment
is working’’ (mean = 1.74), ‘‘I enjoy every day to the full-
est’’ (2.01) and ‘‘I can put some aspects of my life on hold’’
(2.09). For many of the statements, some differences were
observed (though not statistically significant) based on the
patients’ demographic and clinical information. For exam-
ple, respondents diagnosed more recently more often
strongly agreed that they could live with side effects and put
some aspects of their life on hold, as compared to those who
were diagnosed more than 3 years ago. Those diagnosed
[3 years ago also agreed less often with the statement ‘‘I can
take good care of myself.’’ Older patients (those aged 50?)
agreed slightly more frequently with statements about feel-
ing hopeful about the future (2.5 vs. 2.7), having enough
energy (2.6 vs. 2.7), and enjoying every day to the fullest (1.9
vs. 2.2) than did younger patients.
Hypothetical scenarios
When asked to consider QoL, physical functioning, and
emotional well-being for two women in a hypothetical sce-
nario, the large majority of respondents indicated either that
these measures were the same for each woman or that Woman
B’s were superior to Woman A’s. For QoL, 40 % of respon-
dents felt that Woman B had higher QoL, 6 % felt that Woman
A’s QoL was higher, and 54 % felt they were the same
(Table 3). A similar pattern was seen for physical functioning:
more respondents indicated that Woman B’s physical func-
tioning was better than Woman A’s (31 vs. 8 %), while 60 %
indicated that physical functioning was the same (Table 3).
Finally, the majority of respondents (58 %) reported that
Woman B had better emotional well-being than Woman A
(Table 3), a finding that was observable regardless of pro-
gression status (among progressed: 57 %, not progressed:
59 %), age (\50: 58 %, 50?: 58 %) or time since progression
(\1 year: 55 %, 1–3 years: 59 %,[3 years: 61 %).
Respondents who were diagnosed with MBC more recently
(\1 year ago) were significantly more likely to perceive dif-
ferences in the overall QoL for the two women (v2 = 10.02;
df = 4; p = 0.04) as compared to respondents diagnosed more
than 1 year ago. In addition, respondents who were at least
50 years old (vs. those \50, v2 = 9.94; df = 2; p = 0.007)
and those with greater than 3 years since MBC diagnosis (vs.
those \3 years, v2 = 7.17; df = 2; p = 0.028) were more
likely to rate the physical functioning the same for Woman A
and Woman B. There were no significant differences in treat-
ment preference by age or whether their disease had progressed.
When asked which treatment scenario (X or Y) they
would prefer, the majority of respondents [63, 95 % CI
(56.9, 68.2 %)] preferred Treatment Y (i.e., longer time
before progression) over Treatment X. One-quarter [26,
95 % CI (21.0, 31.3 %)] were unsure of their preference,
and 12 % [95 % CI (8.2, 15.7 %)] of respondents indicated
they preferred the treatment with a shorter time to pro-
gression (p value \0.001).
Importance of treatment characteristics
When asked to rank five treatment characteristics from the most
important (1) to the least important (5), respondents indicated
Table 3 Responses to the hypothetical scenario
All Non-progressed Progressed p valuea
n, % (95 % CI) n, % (95 % CI) n, % (95 % CI)
Which woman has better QoL?
Woman A 16, 5.7 % (3.5 %, 9.1 %) 4, 3.3 % (1.3 %, 8.1 %) 12, 7.6 % (4.4 %, 12.8 %)
They are the same 151, 53.9 % (48.1 %, 60.0 %) 66, 54.1 % (45.3 %, 62.7 %) 85, 53.8 % (46.0 %, 61.4 %)
Woman B 113, 40.4 % (34.8 %, 46.2 %) 52, 42.6 % (34.2 %, 51.5 %) 61, 38.6 % (31.4 %, 46.4 %) 0.284
Which woman has better physical functioning?
Woman A 22, 7.9 % (5.3 %, 11.8 %) 5, 4.1 % (1.8 %, 9.3 %) 17, 10.8 % (7.0 %, 16.9 %)
They are the same 167, 59.6 % (54.6 %, 66.1 %) 73, 59.8 % (51.4 %, 68.6 %) 94, 59.5 % (52.8 %, 68.0 %)
Woman B 87, 31.1 % (26.3 %, 37.2 %) 43, 35.2 % (27.6 %, 44.4 %) 44, 27.8 % (21.9 %, 35.9 %) 0.079
Which woman has better emotional well-being?
Woman A 17, 6.1 % (3.9 %, 9.6 %) 5, 4.1 % (1.8 %, 9.4 %) 12, 7.6 % (4.4 %, 12.9 %)
They are the same 99, 35.4 % (30.3 %, 41.5 %) 44, 36.1 % (28.6 %, 45.6 %) 55, 34.8 % (28.0 %, 42.8 %)
Woman B 161, 57.5 % (52.2 %, 63.8 %) 71, 58.2 % (50.2 %, 67.6 %) 90, 57.0 % (49.5 %, 64.8 %) 0.489
a Represents p value for comparison of distribution between progressed and non-progressed groups
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that extending survival was the most important aspect to con-
sider (mean ranking: 1.7 ? 1.1), followed by extending time to
progression (2.4 ? 1.1), reducing the size of the tumor
(2.9 ? 1.3), limiting side effects (3.0 ? 1.3), and finally the
frequency of treatment (4.5 ? 1.1). The same rank order was
observed regardless of disease progression status, age, or time
since MBC diagnosis, with the exception of those diagnosed
[3 years ago. Those patients indicated a slight preference for
limiting side effects (2.8) over reducing the size of the tumor
(3.0). There were no statistically significant differences by
disease progression, age, or time since MBC diagnosis.
QoL ratings
Patients rated their own QoL, physical functioning, and
emotional well-being at different stages of their disease
using a scale ranging from 0 to 100, with 0 being the worst
and 100 the best. Table 4 shows that ratings of overall QoL
were higher after the initial breast cancer diagnosis (68.5)
than after MBC diagnosis (60.3) or when patients were told
that their MBC had progressed (58.4, p value\0.001). The
highest QoL ratings were after respondents were told that
their MBC was responding to treatment (range 75.7–78.0).
Ratings for overall QoL and physical functioning for each
progression level were consistently higher than ratings for
emotional well-being. Emotional well-being was higher
after initial breast cancer diagnosis (60.4) than after MBC
diagnosis (50.7) or MBC progression (50.5).
Respondents who were diagnosed with MBC [3 years
ago reported significantly higher overall QoL (p = 0.032),
physical functioning (p = 0.002), and emotional well-being
(p = 0.027) after being told their MBC had progressed,
compared to those who were diagnosed \3 years. When
stratified by age, emotional well-being was significantly
higher after the initial diagnosis for respondents[50 years
old (p = 0.038) compared to those who were younger. Older
respondents also reported significantly higher overall QoL
(p = 0.001), physical functioning (p = 0.001), and emo-
tional well-being (p = 0.027) compared to those\50 years
of age, during the timeframe after being told their MBC had
progressed. Finally, after being told that their MBC was
responding to treatment, respondents [50 years of age
reported higher overall QoL (p \ 0.001), physical func-
tioning (p \ 0.001), and emotional well-being (p \ 0.001)
than respondents\50 years of age.
Discussion
Findings from this study demonstrate several important
aspects of the MBC population. First, it is clear that the
perceived QoL of these patients is directly correlated with
the status of their disease progression as well as whether
they are responding to treatment. Age and the time since
cancer diagnosis also appear to affect their perception of
overall QoL. Women who were younger rated their QoL as
lower, as did those who were more recently diagnosed,
possibly indicating that patients who have lived with MBC
for a longer period of time do not experience the drop in
QoL that a newly diagnosed patient experiences. At the
Table 4 Mean QoL ratings at time of initial breast cancer diagnosis, MBC diagnosis, and time of progression
Overall Non-progressed Progressed
Mean (SD) Mean (SD) Mean (SD)
Overall QoL
Initial diagnosis of breast cancer (n = 279) 68.5 (30.1) 66.6 (30.8) 70.0 (29.5)
MBC diagnosis (n = 120)a 60.3 (30.9) 59.1 (31.0) 61.2 (31.0)
MBC progression (n = 174) 58.4 (27.8) N/A 60.4 (26.7)
MBC responding (n = 231) 76.6 (17.7) 78.0 (15.7) 75.7 (18.9)
Physical functioning
Initial diagnosis of breast cancer (n = 279) 73.7 (27.3) 74.2 (25.2) 73.2 (28.9)
MBC diagnosis (n = 120)a 63.2 (26.2) 61.9 (25.9) 64.3 (26.4)
MBC progression (n = 174) 61.3 (26.1) N/A 62.4 (25.4)
MBC responding (n = 231) 71.0 (20.4) 71.1 (19.4) 71.0 (21.1)
Emotional well-being
Initial diagnosis of breast cancer (n = 279) 60.4 (32.4) 59.7 (31.9) 61.0 (32.9)
MBC diagnosis (n = 120)a 50.7 (30.3) 46.1 (29.6) 53.9 (30.4)
MBC progression (n = 174) 50.5 (28.2) N/A 51.7 (27.7)
MBC responding (n = 231) 76.8 (18.2) 78.3 (15.7) 75.9 (19.7)
Ratings range from 0 to 100, where 0 represents the worst you can imagine and 100 the best you can imagine
a Excludes those whose initial diagnosis was MBC
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same time, patients strongly agreed with statements
reflecting a positive emotional state, including ‘‘I feel
hopeful about the future’’ and ‘‘I enjoy every day to the
fullest.’’ This implies that while their emotional well-being
may be affected by changes in their disease status (e.g.,
negatively by MBC progression or positively by response
to treatment), in general these patients report experiencing
a relatively high level of QoL. It is difficult to know how
this compares to other MBC populations, as the literature
on patients with MBC is limited.
In terms of their own treatment, patients strongly agreed
that they could ‘‘live with side effects as long as the treat-
ment is working’’ and ‘‘put some aspects of my life on
hold.’’ The fact that patients indicate a willingness to endure
side effects and delay or eliminate aspects of their life for a
treatment that ‘‘is working’’ (i.e., one that extends OS or
PFS) demonstrates the relative value patients place on these
outcomes. Accordingly, when asked to rate the relative
importance of five characteristics of their cancer treatment,
extending OS and PFS were rated as the first and second
most important, on average. Both aspects were rated as
being more important than decreasing tumor size or side
effects, suggesting that patients are willing to endure some
side effects to improve overall treatment outcomes.
When presented with a hypothetical scenario of two
different treatments for two different women, the majority
of respondents (63 %) preferred the treatment with a longer
time before disease progression (16 vs. 12 months). This
suggests that patients consider four additional months of
PFS as an important difference, even when there is no
difference in side effects or OS for the two treatments.
While it is not clear why some patients (12 %) preferred
the treatment with a shorter time before disease progres-
sion, it is possible that they did not consider all aspects of
the scenario (i.e., that the treatments had similar side effect
profiles) or did not fully understand the exercise. If it was
due to a lack of understanding of the scenario or termi-
nology of PFS, it has important implications for physician–
patient communication when it comes to decisions
regarding treatment and outcomes. When asked about
specific aspects of the hypothetical patients’ experience, a
majority of respondents (58 %) felt that the woman whose
treatment had longer PFS had better emotional well-being.
This is noteworthy considering the emotional impact MBC
can have on patients, as mentioned above. While it is true
that most respondents felt that overall QoL (54 %) and
physical functioning (60 %) were the same for both
women, 40 % felt that the woman with 4 months longer
PFS had higher overall QoL and 31 % felt the woman had
better physical functioning. However, patients diagnosed
more than a year prior did not perceive this difference in
QoL again possibly due to their own experiences with
disease progression and its effect on QoL.
There are several limitations to our research that should be
considered. While there are benefits in collecting data using an
online survey, issues such as access and technology-related
challenges can impede the ability to include a representative
sample. Additionally, since women in our study were well
enough to complete the questionnaire, they may have been in
better general health than a typical patient with MBC.
Respondents were asked to retrospectively rate their QoL
during previous time periods, so it is possible that there may be
some recall bias. Additionally, responses reflect the perceived
impact on QoL. Information on treatment therapies (e.g., the
type of chemotherapy agent) was not collected, nor was the
type of breast cancer. Finally, the majority of the Part III
sample was white (88 %) and all patients (per eligibility cri-
teria) were English-speaking, again calling into question the
generalizability of these results and limiting our ability to
investigate potential differences across race categories.
Future research, including the development of scale
scores to replace the individual item-level data as currently
presented, would be worthwhile. Additionally, it would be of
value to confirm these results in a larger, more diverse
sample of women with MBC, and eventually in a prospective
study. We also plan to investigate the value of PFS in dif-
ferent subtypes and clinical presentations of breast cancer.
Conclusions
This is the first study designed to understand the value
women with MBC place on PFS. The MBC-P question-
naire was developed with input from women with MBC
and shows promise in its ability to provide a subjective
measure of the importance of PFS. Respondents in our
study considered PFS an important aspect of treatment and
associated an additional 4 months of PFS with better
overall QoL, physical functioning, and emotional well-
being. To our knowledge, this is the first study to demon-
strate a correlation of PFS with patient-reported QoL.
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Appendix: Sample Items from the MBC-P
Overall health and well being
During the past week, on how many days did the following
apply to you?
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– My health put stress on my relationships.
– I did not feel like being around other people.
– I felt hopeful about the future.
Cancer worry
Overall, how much to you agree or disagree with each
statement?
– I feel like bad news about my cancer is just around the
corner.
– I feel confident that my current treatment will prevent
my cancer from progressing further.
– It is difficult to think about anything other than my cancer.
Limitations
During the past week, how much were you limited in your
ability to…
– be away from home for more than a day?
– think clearly?
– spend time with family or friends?
Hypothetical scenario
‘‘Please think about the following hypothetical situation.
Your doctor suggested a particular treatment for metastatic
breast cancer. Let’s call it Treatment X. Imagine Treatment
X can have two outcomes:
Outcome #1: Treatment X works for one year before
your cancer progresses and you have to switch to a new
treatment. You could have fewer or more side effects
with this new treatment.
Outcome #2: Treatment X works for one year and four
months before your cancer progresses and you have to
switch to a new treatment. You could have fewer or
more side effects with this new treatment.
Imagine the side effects from Treatment X and your
survival are the same with both outcomes.
Q: Which outcome would allow you to have better
overall functioning at the end of Treatment X?
Q: Which outcome would allow you to have better
overall well-being at the end of Treatment X?
Q: Which outcome would you prefer?
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